Relationship of OPRM1 118A/G gene polymorphism and oxycodone analygesic dose in paitents with cancer pain.
10.3760/cma.j.issn.1003-9406.2018.06.027
- Author:
Tao LIN
1
;
Xiangkui LI
;
Junmei SONG
;
Chengshun ZHANG
;
Mingjiang BIE
Author Information
1. Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, China. 13941057@qq.com.
- Publication Type:Journal Article
- MeSH:
Analgesics, Opioid;
administration & dosage;
Cancer Pain;
drug therapy;
Dose-Response Relationship, Drug;
Genotype;
Humans;
Oxycodone;
administration & dosage;
Polymorphism, Single Nucleotide;
Receptors, Opioid, mu;
genetics
- From:
Chinese Journal of Medical Genetics
2018;35(6):887-890
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the relationship between OPRM1 118A/G gene polymorphism and oxycodone analgesic dose in patients with cancer pain.
METHODS:DNA sequencing was used to detect the genotypies of OPRM1 118 A/G site in 203 patients with moderate and severe cancer pain, and to compare the relationship between the pain degree and the dose of oxycodone at 3 and 30 days after treatment in patients with different genotypes.
RESULTS:The fequencies of AA, AG and GG genotypes at the OPRM1 118 A/G site were 34.78%, 52.70%, and 12.52%, respectively. The dosage of oxycodone in GG genotype was significantly higher than that in AA genotype and AG genotype (15.44±10.19 vs. 10.25±4.53, 10.49±5.26; 89.15±27.69 vs. 43.59±12.19, 48.27±18.79) on the 3 and 30 day after treatment, difference was statistically significant (P< 0.05).
CONCLUSION:For cancer pain patients with GG genotype of OPRM1 118A/G site, if they need to achieve the same analgesic effect as patients with AA and AG genotype, the dose of oxycodone should be increased.
